Brief: BB Biotech Reports Net Profit Of CHF 451 Mln In Q2 2026
24/07/2026 06:05
BRIEF-BB Biotech Reports Net Profit Of CHF 451 Mln In Q2 2026 July 24 (Reuters) - BB BIOTECH AG BION.S:
Q2 2026: STRONG NAV OUTPERFORMANCE DRIVEN BY DISCIPLINED STOCK SELECTION AND PORTFOLIO POSITIONING
Q2 2026 NAV TOTAL RETURN +17.2% IN CHF, OUTPERFORMS NBI BY 3.5 POINTS
REPORTS NET PROFIT OF CHF 451 MILLION IN Q2 2026
Q2 2026 SHARE PRICE TOTAL RETURN +9.7% IN CHF
REVISES ANNUAL DIVIDEND POLICY FOR FY2026, TARGETS DIVIDEND YIELD OF 3-5%
Source text: ID:nEQ4dyZx9a
Further company coverage: BION.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Bb Biotech AG
See all newsBrief: BB Biotech Reports Net Profit Of CHF 451 Mln In Q2 2026
Switzerland's BB Biotech Q1 net loss narrows amid portfolio rotation
Brief: BB Biotech Reports Q1 Net Loss Of CHF 21 Million
Brief: BB BIOTECH Q1 Net Income CHF -21 Million
Brief: BB Biotech Says All Proposals Of Board Of Directors Approved At AGM